Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
Clinical trial NCT04976192 · COMPLETED
Trial details
- NCT number
- NCT04976192
- Sponsor
- Teva Pharmaceuticals USA
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-30
- Primary completion
- 2024-04-05
- Enrollment
- 608
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.